Charity D. Scripture

Author

National Cancer Institute

Also Known As

C SCRIPTURE, C. D. Scripture, C. Scripture, Charity D Scripture, Charity D. Scripture, Charity Scripture

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research University of Chicago AbbVie (United States)

About

Charity D. Scripture is an author at National Cancer Institute specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	439
2	Immunology	3	3	57
3	Natural Sciences	1	1	11
4	Biochemistry	1	1	11
5	Cell Biology	1	1	29

Charity D. Scripture

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) Alex Sparreboom, Charity D. Scripture, Vuong Trieu, Clinical Cancer Research	2005	492
Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives Charity D. Scripture, William D. Figg, Alex Sparreboom Current Neuropharmacology Peripheral Nerve InjuryNeuropathic PainPathologyPharmacotherapyPeripheral Nerves	2006	318
Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and<i>nab</i>-Paclitaxel Erin R. Gardner, William L. Dahut, Charity D. Scripture, Clinical Cancer Research	2008	216
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer William L. Dahut, Charity D. Scripture, Edwin M. Posadas, Clinical Cancer Research	2008	178
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy Charity D. Scripture, William D. Figg, Alex Sparreboom Therapeutics and Clinical Risk Management	2005	80
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer Hibiki Udagawa, Hiroaki Akamatsu, Kentaro Tanaka, Lung Cancer Japanese PatientsOncologyMedicinePathologyImmune Checkpoint Inhibitor	2019	31
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Nature Communications Cancer ManagementImmunologyPharmacotherapyPancreatic CancerOncology	2024	29
Bony metastatic disease responses to sorafenib (BAY 43–9006) independent of PSA in patients with metastatic androgen independent prostate cancer William L. Dahut, Charity D. Scripture, Edwin M. Posadas, Journal of Clinical Oncology UrologyGenitourinary CancerMedicineRadiographic MeasurementsCancer Cell Biology	2006	22
Activities of Cytochrome P450 1A2, <i>N</i>‐acetyltransferase 2, Xanthine oxidase, and Cytochrome P450 2D6 are Unaltered in Children with Cystic Fibrosis Mary Jayne Kennedy, Charity D. Scripture, Angela D. M. Kashuba, Clinical Pharmacology & Therapeutics	2004	21
AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors Peter J. Rosen, Chris Sweeney, D. J. Park, Journal of Clinical Oncology Amg 102ImmunologyPathologyHgf/sf AntagonistImmunotherapeutics	2008	16

Page 1